Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cassiopea S.p.A.    SKIN   IT0005108359

CASSIOPEA S.P.A.

(SKIN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/17/2020 11/18/2020 11/19/2020 11/20/2020 11/23/2020 Date
46(c) 47(c) 46.9(c) 46.5(c) 46(c) Last
272 777 6 400 2 659 3 932 1 658 Volume
-1.08% +2.17% -0.21% -0.85% -1.08% Change
More quotes
Financials
Sales 2020 - - -
Net income 2020 -14,2 M -16,8 M -16,8 M
Net cash position 2020 2,00 M 2,37 M 2,37 M
P/E ratio 2020 -35,3x
Yield 2020 -
Sales 2021 36,7 M 43,6 M 43,6 M
Net income 2021 -36,6 M -43,5 M -43,5 M
Net cash position 2021 6,00 M 7,12 M 7,12 M
P/E ratio 2021 -12,7x
Yield 2021 -
Capitalization 430 M 510 M 511 M
EV / Sales 2020 -
EV / Sales 2021 11,6x
Nbr of Employees 12
Free-Float 40,7%
More Financials
Company
Cassiopea SpA is an Italy-based company engaged in the biotechnology and medical research industry. The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. The Company's current focus is on the topical treatment of acne, androgenic alopecia (''AGA'') and genital warts. Its portfolio comprises four clinical... 
More about the company
Notations Surperformance© of Cassiopea S.p.A.
Trading Rating : Investor Rating : -
More Ratings
All news about CASSIOPEA S.P.A.
11/17CASSIOPEA S P A : Credit Suisse & Jefferies Presentation
PU
11/12CASSIOPEA S P A : Credit Suisse & Jefferies Presentation
PU
10/10CASSIOPEA S P A : Announces completion of enrollment in a phase ii trial of clas..
AQ
10/08Cassiopea Announces Completion of Enrollment in a Phase II Trial of Clascoter..
TE
09/14Cassiopea to present at the H.C. Wainwright Global Investment Conference
TE
08/29COSMO PHARMACEUTICALS N : announces FDA Approval for Cassiopea's Winlevi, First-..
AQ
08/29CASSIOPEA S P A : Receives fda approval for winlevi, first-in-class topical acne..
AQ
08/28GLOBAL MARKETS LIVE: Rising tensions
08/27Cassiopea gets U.S. FDA approval for acne treatment Winlevi
RE
08/27CASSIOPEA S P A : Receives FDA Approval for Winlevi ® (clascoterone cream 1%), F..
PU
08/27Cassiopea Receives FDA Approval for Winlevi® (clascoterone cream 1%), First-i..
TE
07/29Cassiopea Announces Results for First Half of 2020
TE
06/23Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Saf..
TE
06/18Cassiopea announces that SIX has informed it that trading of its shares is su..
TE
06/18Cassiopea announces completion of the rights offering – gross proceeds ..
TE
More news
News in other languages on CASSIOPEA S.P.A.
10/08Cassiopea boucle le recrutement de patientes pour une phase II contre l'alopé..
10/08Cassiopea schliesst Patienten-Rekrutierung für Studie zu Alopezie ab
10/08Cassiopea gibt Abschluss der Rekrutierung in der Phase II klinischen Versuchs..
08/28CASSIOPEA : commercialisation en mars aux Etats-Unis du Winlevi (CEO)
08/28Quand les poules auront des dents !
More news
Chart CASSIOPEA S.P.A.
Duration : Period :
Cassiopea S.p.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CASSIOPEA S.P.A.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 66,15 €
Last Close Price 43,03 €
Spread / Highest target 95,8%
Spread / Average Target 53,7%
Spread / Lowest Target 30,4%
EPS Revisions
Managers
NameTitle
Diana Harbort Chief Executive Officer & Executive Director
Jan Egbert de Vries Non-Executive Chairman
Marco Pasero Chief Operating Officer
Hans Christoph Tanner Chief Financial Officer & Head-Media Relations
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CASSIOPEA S.P.A.10.71%510
GILEAD SCIENCES, INC.-7.49%75 350
VERTEX PHARMACEUTICALS-1.71%55 963
REGENERON PHARMACEUTICALS38.15%54 750
WUXI APPTEC CO., LTD.65.81%40 457
BEIGENE, LTD.71.43%25 903